je.st
news
Tag: clinical
Immunocore And Lilly Announce Immunotherapy-Based Clinical Trial Collaboration In Melanoma
2015-07-01 08:13:50| drugdiscoveryonline Home Page
Immunocore Limited and Eli Lilly and Company recently announced that they have entered into an immunotherapy-based clinical trial collaboration to explore the utility of Immunocore’s lead T-cell receptor based investigational therapeutic, IMCgp100, in combination with Lilly’s galunisertib (LY2157299) and merestinib (LY2801653) for the treatment of melanoma
Tags: trial
clinical
collaboration
announce
\"Live-Topical\" Acne Treatment In Phase 2 Clinical Testing
2015-06-23 07:01:00| Happi Breaking News
What is AOBiome's B244 all about?
Tags: treatment
phase
testing
clinical
Axovant Sciences - The Late Clinical Stage Biotech With Huge IPO Potential
2015-06-09 21:00:38| Biotech - Topix.net
Axovant Sciences is a late-stage clinical trial biotech preparing for its initial public offering the week of June 8. The company's lead drug candidate is an Alzheimer's treatment currently in Phase 3 trials. Axovant acquired the intellectual property and rights from GlaxoSmithKline .
Tags: potential
late
stage
huge
Ichor Partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical...
2015-06-02 21:34:40| Logistics - Topix.net
Ichor Medical Systems, Inc. is pleased to announce that their partner Scancell Holdings plc presented updated and very encouraging data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNAi 1 2ImmunoBody being developed for the treatment of patients with melanoma, at the American Society of Clinical Oncology meeting in Chicago. The trial is ani 1 2open label, non-randomized study to characterize the safety and tolerability of SCIB1 administeredi 1 2using Ichor's TriGridTM delivery system, as well as provide initial assessment of the ability of SCIB1 to delay ori 1 2prevent disease recurrence in patients with Stage III/IV melanoma.
Tags: partner
update
phase
clinical
Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial ...
2015-06-01 20:27:17| Biotech - Topix.net
Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has begun enrolling patients in a Phase 2b clinical trial to evaluate Apricus' novel product candidate, fispemifene, a selective estrogen receptor modulator , for the treatment of men with symptomatic secondary hypogonadism also known as low testosterone. The Phase 2 proof-of-concept clinical trial is a randomized, double-blind, placebo-controlled, parallel arm, multi-center study in approximately 160 hypogonadal men aged 18 to 64 who present with sexual dysfunction related to secondary hypogonadism, or low levels of testosterone.
Tags: trial
phase
patients
clinical
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »